Which of your patients with acromegaly is right for Somatuline Depot (lanreotide) Injection?

Somatuline Depot is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to:

Surgery
Radiation

Somatuline Depot is also for patients who cannot tolerate surgery or radiation treatments.1

Could Somatuline Depot help your patients?

Last year Somatuline Depot helped over 6000 patients with acromegaly,2 patients such as Dave, Mark, and Karen. See if your patients are like:

Support for patients taking Somatuline Depot

Somatuline Depot is widely available, including through specialty pharmacies and is expected to be covered by most pharmacy benefit plans.2 Learn more about the reimbursement support for patients on Somatuline Depot.

How to inject Somatuline Depot

Somatuline Depot is injected in an easy, two-step injection process.1 Learn more about injecting Somatuline Depot.

Safety and tolerability of Somatuline Depot

Somatuline Depot is well-tolerated and had a 1.9% discontinuation rate in a 52-week study.1,2 Learn more about the safety and tolerability of Somatuline Depot.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).